It is reasonable to assume that the threshold for indicating HSCT will change in the coming years, with an increasing proportion of patients choosing pre-emptive HSCT, in particular due to the high risk of progression in GATA2-related MDS. The gene discussed is GATA2; the disease is myelodysplastic syndrome.